Ericancer.org - A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in

Provided by Alexa ranking, ericancer.org has ranked N/A in N/A and 1,424,798 on the world. ericancer.org reaches roughly 2,192 users per day and delivers about 65,761 users each month. The domain ericancer.org uses a Commercial suffix and it's server(s) are located in N/A with the IP number N/A and it is a .org domain.

WebMay 25, 2020 · Breast Cancer—Metastatic. May 25, 2020. A phase Ib/II study of eribulin (ERI) plus … Author: Sara M. Tolaney, Kevin Kalinsky, Virginia G. Kaklamani, David R. D'Adamo, Gursel Aktan, Michaela L. ... Publish Year: 2020

Search Results related to ericancer.org on Search Engine

A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in
ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.1015

WebMay 25, 2020 · Breast Cancer—Metastatic. May 25, 2020. A phase Ib/II study of eribulin (ERI) plus … Author: Sara M. Tolaney, Kevin Kalinsky, Virginia G. Kaklamani, David R. D'Adamo, Gursel Aktan, Michaela L. ... Publish Year: 2020

Author: Sara M. Tolaney, Kevin Kalinsky, Virginia G. Kaklamani, David R. D'Adamo, Gursel Aktan, Michaela L. ...
Publish Year: 2020

DA: 72 PA: 44 MOZ Rank: 47

Exceptional Responders Q and A - NCI - National Cancer Institute
cancer.gov

https://www.cancer.gov/about-cancer/treatment/research/exceptional-responders-initiative-qa

WebThe National Cancer Institute (NCI) embarked on the Exceptional Responders Initiative (ERI) to understand the …

DA: 28 PA: 85 MOZ Rank: 99

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple
nih.gov

https://pubmed.ncbi.nlm.nih.gov/33727258/

WebJun 1, 2021 · Abstract. Purpose: As monotherapies, eribulin (chemotherapy) and pembrolizumab (immunotherapy) … Author: Sara M. Tolaney, Kevin Kalinsky, Virginia G. Kaklamani, David R. D'Adamo, Gursel Aktan, Michaela L. ... Publish Year: 2021

Author: Sara M. Tolaney, Kevin Kalinsky, Virginia G. Kaklamani, David R. D'Adamo, Gursel Aktan, Michaela L. ...
Publish Year: 2021

DA: 64 PA: 46 MOZ Rank: 39

Network meta-analysis of eribulin versus other ... - BMC Cancer
biomedcentral.com

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08446-8

WebJun 30, 2021 · Eribulin mesylate (ERI; Halaven®) is a microtubule inhibitor approved in the United States for … Author: Qi Zhao, Rachel Hughes, Binod Neupane, Kristin Mickle, Yun Su, Isabelle Chabot, Marissa Betts, Anant... Publish Year: 2021

Author: Qi Zhao, Rachel Hughes, Binod Neupane, Kristin Mickle, Yun Su, Isabelle Chabot, Marissa Betts, Anant...
Publish Year: 2021

DA: 49 PA: 48 MOZ Rank: 55

Abstract - American Association for Cancer Research
aacrjournals.org

https://aacrjournals.org/cancerres/article/78/4_Supplement/PD6-13/633029/Abstract-PD6-13-Phase-1b-2-study-to-evaluate

WebFeb 15, 2018 · Background: Eribulin mesylate (ERI), a nontaxane microtubule inhibitor with effects on tumor biology …

DA: 25 PA: 59 MOZ Rank: 67

ERI Cancer (@eri_cancer) | Twitter
twitter.com

https://mobile.twitter.com/eri_cancer

WebFeb 5, 2015 · The latest Tweets from ERI Cancer (@eri_cancer): "Novel Drug Approved for Breast Cancer: …

DA: 88 PA: 88 MOZ Rank: 14

THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rec…
biomedcentral.com

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-09158-9

WebJan 15, 2022 · Recently, an early tumour regression index (ERI) was introduced to predict pathological CR (pCR) after …

DA: 39 PA: 17 MOZ Rank: 64

Natural product Eriocalyxin B suppressed triple ... - ScienceDirect
sciencedirect.com

https://www.sciencedirect.com/science/article/pii/S0006295223000825

WebApr 1, 2023 · Eriocalyxin B (Eri B), an ent-kaurane diterpenoid isolating from Isodon eriocalyx var. laxiflora, has previously …

DA: 28 PA: 1 MOZ Rank: 80

Alexa Rank

GLOBAL RANK

1,424,798

Alexa Reach

0.0000967654

Page length

N/A

Alexa Rank Country N/A

N/A

Daily Unique Visitors

2,192

Monthly Unique Visitors

65,761

Vistor via Country

Country lang

Country code

Total visitor

Country

Country code

Total visitor

United States

14,066

Indonesia

11,002

Taiwan

3,577

United Kingdom

3,176

Brazil

2,874

Nigeria

2,512

Egypt

2,111

Hong Kong

1,993

Canada

1,993

Australia

1,736

Philippines

1,243

India

1,210

Malaysia

1,190

Spain

986

Germany

960

Mexico

921

France

868

Italy

802

Turkey

737

Iraq

671

Thailand

658

Netherlands

631

Israel

625

Cambodia

520

Algeria

401

Ireland

362

Romania

349

Jordan

322

Poland

309

Ghana

296

Argentina

283

South Africa

256

Belgium

230

Czechia

210

Ukraine

197

Japan

197

Morocco

191

South Korea

184

Lebanon

178

Saudi Arabia

171

Austria

164

Hungary

158

Sweden

151

Singapore

145

Pakistan

138

Bangladesh

132

Denmark

125

Greece

118

Alexa Traffic Graph

Alexa daily traffic trend graph

Alexa Statistics Graph for ericancer.org

Alexa daily pageviews (percent) graph

Alexa Statistics Graph for www.nahklick.de

Alexa daily pageviews per user graph

Alexa time on site (in minutes) graph

Alexa bounce rate (percent) graph

Alexa search visits graph

SEOquake Zone

Title			Tips
Description			Tips
Keywords			Tips
Viewport			Tips
Icon
UTF-8

Mini site formation by Alexa Rank

MOZ Rank

Semcrush Traffic Graph

Semrush Statistics Graph for ericancer.org

DNS Record

Host	Type	Class	TTL	Extra

Hosting and Whois Zone

Domain infomation	Domain not found. >>> Last update of WHOIS database: 2024-04-24T18:55:12Z <<< Terms of Use: Access to Public Interest Registry WHOIS information is provided to assist persons in determining the contents of a domain name registration record in the Public Interest Registry registry database. The data in this record is provided by Public Interest Registry for informational purposes only, and Public Interest Registry does not guarantee its accuracy. This service is intended only for query-based access. You agree that you will use this data only for lawful purposes and that, under no circumstances will you use this data to (a) allow, enable, or otherwise support the transmission by e-mail, telephone, or facsimile of mass unsolicited, commercial advertising or solicitations to entities other than the data recipient's own existing customers; or (b) enable high volume, automated, electronic processes that send queries or data to the systems of Registry Operator, a Registrar, or Identity Digital except as reasonably necessary to register domain names or modify existing registrations. All rights reserved. Public Interest Registry reserves the right to modify these terms at any time. By submitting this query, you agree to abide by this policy. The Registrar of Record identified in this output may have an RDDS service that can be queried for additional information on how to contact the Registrant, Admin, or Tech contact of the queried domain name.